Drug Profile
Research programme: anti-infectives - Inimex
Alternative Names: Immucept; IMX 001; IMX 003Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Inimex Pharmaceuticals
- Class Peptides; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections; Community-acquired pneumonia; Nosocomial pneumonia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Community-acquired-pneumonia in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Nosocomial-pneumonia in Canada (IV)